Julie Foote, MD
Endocrinology, Diabetes & Metabolism · Boise, IDNPI 1104836303
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,263 of the $7,556 with a category attached, or 69.6%. Abbott accounts for 75.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $4,123 and has fallen 99.3% since, to $30 in 2025.
Across 123 payments — averaging $61.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Novo Nordisk$528
- Amgen$444
- Medtronic$211
- Ascendis Pharma Endocrinology Inc$125
- Shire North American Group Inc$115
- plus $450 from 7 others
What the payments were for
- Speaking & faculty fees$5,26370%
- Food & beverage$2,29330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $5,683 |
| Novo Nordisk | 71 | $528 |
| Amgen | 6 | $444 |
| Medtronic(2 entities) | 3 | $211 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Shire North American Group Inc | 1 | $115 |
| Dexcom, Inc. | 5 | $114 |
| Lilly USA, LLC | 6 | $103 |
| Radius Health, Inc. | 1 | $56 |
| Tandem Diabetes Care, Inc. | 2 | $55 |
| Recordati_rare_diseases_inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Insulet Corporation | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre Pro$5,388
- EVENITY$216
- InPen$160
- Yorvipath$125
- NATPARA (PARATHYROID HORMONE)$115
- Prolia$102
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $128,946 |
| JardianceEmpagliflozin | 84 | $84,858 |
| TrulicityDulaglutide | 68 | $80,285 |
| MounjaroTirzepatide | 41 | $42,700 |
| FarxigaDapagliflozin Propanediol | 27 | $30,732 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 40 | $22,773 |
| JanuviaSitagliptin Phosphate | 17 | $18,671 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $16,880 |
| Testosterone | 29 | $11,684 |
| Novolog FlexpenInsulin Aspart | 34 | $10,369 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $10,164 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 25 | $8,635 |
| NovologInsulin Aspart | 37 | $8,171 |
| Cabergoline | 29 | $7,536 |
| Levothyroxine Sodium | 648 | $7,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $528 | $137,116146 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $103 | $126,202134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Boise
- Theodore RooseveltBoise$65K
- Shanaz SikderBoise$3K
- Richard ChristensenBoise$2K
- Robert MinnsBoise$644
- Robert EnnisMeridian$69K
- David LiljenquistIdaho Falls$9K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Angelo CapricchioneBlackfoot$2K
- Michael HolyoakMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.